-
公开(公告)号：US09777020B2
公开(公告)日：2017-10-03
申请号：US14603043
申请日：2015-01-22
Applicant: AbbVie Inc.
Inventor： Robert J. Altenbach , Huaqing Liu , Bruce Clapham , Ana L. Aguirre , Marlon Cowart , John R. Koenig , Kathy Sarris , Marc J. Scanio , Kerren K. Swinger , Anil Vasudevan , Clara I. Villamil , Kevin R. Woller
IPC: C07D407/12 , C07D491/048 , C07D491/20 , C07D519/00 , C07D307/83 , C07D405/12 , C07D491/107 , C07D493/10
CPC classification number: C07D519/00 , C07D307/83 , C07D405/12 , C07D407/12 , C07D491/048 , C07D491/107 , C07D491/20 , C07D493/10
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
2.发明授权6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use 有权6-芳基氧基 - 或6-芳氧基 - 喹啉-2-甲酰胺及其使用方法公开(公告)号：US09452986B2
公开(公告)日：2016-09-27
申请号：US14613579
申请日：2015-02-04
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D401/12 , C07D409/14 , C07D487/08 , C07D401/14 , C07D487/04 , C07D405/14 , C07D417/14 , C07D471/04 , C07D405/12 , C07D409/12 , C07D417/12
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
3.发明申请6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE 有权6-异亮氨酸或6-芳基喹啉-2-羧酸酰胺及其使用方法公开(公告)号：US20160355482A1
公开(公告)日：2016-12-08
申请号：US15239554
申请日：2016-08-17
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D409/14 , C07D487/08 , C07D471/04 , C07D487/04 , C07D405/14 , C07D417/14 , C07D401/12 , C07D401/14
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Abstract translation: 和其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2和R3如说明书中所定义，可用于治疗由电压门控钠通道（例如Nav1）预防或改善的病症或病症。 7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
-
公开(公告)号：US20180334435A1
公开(公告)日：2018-11-22
申请号：US15952682
申请日：2018-04-13
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D487/04 , C07D405/12 , C07D487/08 , C07D401/12 , C07D471/04 , C07D417/14 , C07D405/14 , C07D409/14 , C07D401/14 , C07D409/12 , C07D417/12
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
公开(公告)号：US20170226062A9
公开(公告)日：2017-08-10
申请号：US15239554
申请日：2016-08-17
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D409/14 , C07D487/08 , C07D471/04 , C07D487/04 , C07D405/14 , C07D417/14 , C07D401/12 , C07D401/14
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
Patent Agency Ranking
公开(公告)号：US20160120841A1
公开(公告)日：2016-05-05
申请号：US14925649
申请日：2015-10-28
Applicant: AbbVie Inc.
Inventor： Philip R. Kym , Xueqing Wang , Xenia B. Searle , Bo Liu , Ming C. Yeung , Robert J. Altenbach , Eric Voight , Andrew Bogdan , John R. Koenig
IPC: A61K31/353 , A61K45/06 , C07D405/14 , A61K31/4433 , C07D491/052 , A61K31/435 , A61K31/4025 , A61K31/453 , C07D413/14 , A61K31/5377 , A61K31/397 , C07D491/107 , C07D407/12 , A61K31/436
CPC classification number: C07D407/12 , A61K31/00 , A61K31/353 , A61K31/397 , A61K31/4025 , A61K31/435 , A61K31/436 , A61K31/4433 , A61K31/453 , A61K31/5377 , A61K45/06 , C07D405/14 , C07D413/14 , C07D491/052 , C07D491/107 , A61K2300/00
Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中R1，X，Y，R4，R5，R6，R7，R8，R9，R10，R11，R12，R13，R14，m和R“具有定义的任何值 在本说明书及其药学上可接受的盐中，其可用作治疗由CFTR介导和调节的疾病和病症的药剂，包括囊性纤维化，Siegren综合征，胰腺功能不全，慢性阻塞性肺病和慢性阻塞性气道疾病。 还提供了由一种或多种式（I）化合物组成的药物组合物。
-
公开(公告)号：US09783527B2
公开(公告)日：2017-10-10
申请号：US14854433
申请日：2015-09-15
Applicant: AbbVie Inc.
Inventor： Jerome F. Daanen , David A. DeGoey , Jennifer M. Frost , John R. Koenig , Steve Latshaw , Mark Matulenko , Marc Scanio , Lei Shi , William H. Bunnelle
IPC: A61K31/497 , A61K31/4178 , A61K31/4985 , C07D403/04 , C07D403/14 , C07D487/14 , C07D491/08 , C07D413/14 , C07D405/14 , C07D417/14 , C07D401/14
CPC classification number: C07D403/14 , A61K31/4178 , A61K31/497 , A61K31/4985 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/14 , C07D491/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
公开(公告)号：US20160075692A1
公开(公告)日：2016-03-17
申请号：US14854433
申请日：2015-09-15
Applicant: AbbVie Inc.
Inventor： Jerome F. Daanen , David A. DeGoey , Jennifer M. Frost , John R. Koenig , Steve Latshaw , Mark Matulenko , Marc Scanio , Lei Shi , William H. Bunnelle
IPC: C07D403/14 , C07D401/14 , C07D405/14 , C07D491/08 , C07D413/14 , C07D403/04 , C07D417/14
CPC classification number: C07D403/14 , A61K31/4178 , A61K31/497 , A61K31/4985 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/14 , C07D491/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中A，R 1和R 2如说明书中所定义，可用于治疗由电压门控钠通道预防或改善的病症或障碍 ，例如Nav1.7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
-
9.发明申请FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE 有权FURO-3-CARBOXAMIDE DORIVATIVES AND METHODS OF USE公开(公告)号：US20150210720A1
公开(公告)日：2015-07-30
申请号：US14603043
申请日：2015-01-22
Applicant: AbbVie Inc.
Inventor： Robert J. Altenbach , Huaqing Liu , Bruce Clapham , Ana L. Aguirre , Marlon Cowart , John R. Koenig , Katerina Sarris , Marc J. Scanio , Kerren K. Swinger , Anil Vasudevan , Clara I. Villamil , Kevin R. Woller
IPC: C07D519/00 , C07D493/10 , C07D405/12 , C07D491/20 , C07D307/83 , C07D491/048 , C07D491/107
CPC classification number: C07D519/00 , C07D307/83 , C07D405/12 , C07D407/12 , C07D491/048 , C07D491/107 , C07D491/20 , C07D493/10
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，Z1，Z2和n如说明书中所定义，可用于治疗由Tropomysin受体阻止或改善的病症或病症 激酶（Trk）。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
-
公开(公告)号：US09969693B2
公开(公告)日：2018-05-15
申请号：US15239554
申请日：2016-08-17
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D401/12 , C07D409/14 , C07D487/08 , C07D401/14 , C07D487/04 , C07D405/14 , C07D417/14 , C07D471/04
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.034 seconds)
